Navigation Links
FDA Agrees to Amend Dendreon's Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
Date:3/12/2008

-Amended Agreement Accelerates Expected Timing of Final Analysis by One Year While Maintaining Comparable Powering of Interim and Final Results- -Dendreon to Hold Conference Call on Thursday, March 13, 2008 at 11:00 AM

ET-

SEATTLE, March 12 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that the U.S. Food and Drug Administration (FDA) has agreed to an amended Special Protocol Assessment (SPA) for the Phase 3 IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment, also known as D9902B) clinical trial of PROVENGE(R) (sipuleucel-T), the Company's investigational active cellular immunotherapy for the treatment of advanced prostate cancer. In addition, the FDA has reconfirmed that they would accept a positive interim or final analysis from the IMPACT trial to amend the Biologics License Application (BLA) for licensure of PROVENGE.

The amended SPA accelerates the expected timing of the final IMPACT results by approximately one year while maintaining comparable powering of the study's interim and final results. By increasing the number of events and decreasing the alpha (false positive error) spending function for the interim analysis, the Company is able to reduce the number of events for the final analysis (from 360 to 304) and still maintain a comparable statistical power for both the interim and final analyses. Interim results are still expected in the second half of 2008; however, final results are now expected in the second half of 2009 rather than 2010.

Based on the statistical plan in the amended SPA, if the treatment effect at the interim analysis for the IMPACT trial is consistent with the integrated results of the previous two completed pha
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. FDA Agrees to Review Cimzia(R) File for the Treatment of Rheumatoid Arthritis
2. Inverness Medical Innovations Agrees to Acquire ParadigmHealth
3. Inverness Medical Innovations Agrees to Acquire Panbio Ltd.
4. Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
5. Mylan Announces Amendment to Bystolic(TM) (Nebivolol) Agreement
6. Neurobiological Technologies Announces Amendment of License and Cooperation Agreement with Merz Pharmaceuticals and Childrens Hospital
7. Barr Confirms Patent Challenge of Namenda(R) Tablets, 5mg & 10mg
8. ExonHit and bioMerieux Amend Their Strategic Partnership
9. Halozyme Therapeutics Amends Stockholder Rights Plan
10. Beanstalk Capital Ltd. and iCo Therapeutics Inc. amend arrangement agreement
11. Genmab Amends HuMax-CD4 Pivotal Study in CTCL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2014)... 2014 Deep Research Report on Global ... in-depth research report on the China Linalool market. ... its definition, classification, application, and industry chain structure ... the international market analysis, including China’s domestic market ... environment & economic situation analysis. The report on ...
(Date:8/18/2014)... Sterne, Kessler, Goldstein & Fox P.L.L.C. , an intellectual ... , announced today that it has filed eleven petitions ... U.S. Patent and Trademark Office (USPTO) on behalf of ... BRLI).  These IPR petitions aim to nullify eleven patents ... patents have been asserted against GeneDx in patent infringement ...
(Date:8/18/2014)... According to the new ... (Municipal Wastewater Treatment and Industrial Wastewater Treatment), By ... By Configuration (Internal/Submerged and External/Sidestream), and By Region-Trends ... market for membrane bioreactor systems is projected to ... CAGR of 15.28% between 2014 and 2019. ...
(Date:8/18/2014)... 18. August 2014 Vier führende ... internationale klinische Studie auf, in der eine ... soll das Sehvermögen bei allen Entfernungen verbessern, ... möglicherweise keine Lese- oder Gleitsichtbrille mehr benötigen. ... FluidVision Accommodating Intraocular Lens (FluidVision ...
Breaking Biology Technology:Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 2Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 3Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 4Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 2Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 3Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 2Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 3Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 2Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 3Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 4
... Ariz., April 23 ImaRx Therapeutics,Inc. (Nasdaq: ... into an agreement,with Abbott Laboratories pursuant to which ... non-recourse promissory note with Abbott issued in,connection with ... title to,the urokinase assets, including the remaining inventory ...
... (NYSE: SGP ) today announced two agreements ... in Europe. These agreements are,in connection with conditions ... its October 2007 clearance of Schering-Plough,s acquisition of ... In two separate agreements, Pfizer and Virbac, ...
... today,announced that on April 22, 2008 its management ... Emerging Business Awards, known as the "Bennies.",BioNanomatrix won ... group of growing entrepreneurial firms in the Philadelphia ... the,award on behalf of the company., The ...
Cached Biology Technology:ImaRx Therapeutics Satisfies Abbott Note Obligation Associated With the Acquisition of Urokinase 2ImaRx Therapeutics Satisfies Abbott Note Obligation Associated With the Acquisition of Urokinase 3Schering-Plough Announces Planned Divestiture of Select Animal Health Products in Europe 2BioNanomatrix Named 'Best Management Team' at the 2008 Ben Franklin Emerging Business Awards 2
(Date:8/19/2014)... other science courses are increasingly being asked to ... have a new textbook to help them do ... month by Princeton Press and co-authored by scientists ... Synthesis (NIMBioS), teaches readers about basic mathematical and ... and explain biological phenomena. , Suitable for entry-level ...
(Date:8/19/2014)... LIVERPOOL, UK 19 August 2014: An engineer at ... around, despite not having a brain to communicate with ... at Harvard, Professor L Mahadevan, has developed a mathematical ... traditional view of how these soft bodied animals get ... of the central pattern generator (CPG) which states that ...
(Date:8/19/2014)... to treat pain, but its effect on pain ... a recent study reported on the Neural ... rat models of an avulsion injury to the ... neuropathic pain) were given electroacupuncture stimulation at bilateral ... (GB34). After electroacupuncture therapy, chronic neuropathic pain in ...
Breaking Biology News(10 mins):New textbook introduces undergraduates to mathematics for the life sciences 2Secrets of how worms wriggle uncovered 2
... have elucidated a key mechanism by which cancer cells ... and raw materials required to sustain runaway growth. ... Ludwig Cancer Research study also reveals how the aggressive ... therapies that should disrupt this capabilityknown as the Warburg ...
... animals will choose to steer clear of dirt but their ... risk of disease as a result. A study of ... near to used nesting material and droppings left by other mice. ... opportunity to eat outweighs an increased risk of disease from other ...
... to learn that individual "molecular muscles" within cells respond to ... cells "feel" the environment and appropriately adapt their shapes and ... 20 in the journal Nature Materials , specifically sheds ... internal signals. A computer model the researchers developed, ...
Cached Biology News:Targeting cancer's sweet tooth 2Targeting cancer's sweet tooth 3Clean living is a luxury wild animals can't afford, study suggests 2Cells' 'molecular muscles' help them sense and respond to their environments 2Cells' 'molecular muscles' help them sense and respond to their environments 3
PFK-2 car (P-17)...
... contains 5 ml Dynabeads Epoxy (4.5 m). ... (epoxy) reactive groups. Ideal for coupling of ... hydrophobically on initial coupling with covalent binding ... and sulphydryll groups (SH)) occurring within 16-20 ...
LTBP-2 (7B10)...
... [198C679.2.1] to Presenilin 2 Alzheimer's disease ... the disease carry mutations in the presenilin ... protein (APP). These disease-linked mutations result in ... amyloid-beta (main component of amyloid deposits found ...
Biology Products: